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Abstract
Background The pharmacokinetics of vancomycin, a drug used for the treatment of methicillin-resistant Staphylococcus 
aureus (MRSA), varies between paediatric and adult patients.
Objective The objective of this study was to assess the pharmacokinetics of vancomycin in preterm neonates and determine 
the optimum dose regimen.
Methods This was a randomised double-blind study of preterm neonates admitted to neonatal intensive care units. They 
all received vancomycin 15 mg/kg every 12 h. Blood was sampled just before administration of the third, sixth and ninth 
vancomycin dose. Pharmacokinetic parameters were estimated using a Bayesian approach implemented in Monolix 2018R2 
software. Covariates assessed included postmenstrual age, current weight, creatinine clearance, albumin, gestational age, 
body surface area and current age. We used Monte Carlo simulations for dose regimen optimisation targeting area under the 
concentration–time curve up to 24 h (AUC 0–24h) of ≥ 400 mg × h/L.
Results In total, 19 preterm neonates were enrolled in the study with a median age of 14 (3–58) days. A one-compartment 
model with linear elimination best described the pharmacokinetics of vancomycin. Volume of distribution and clearance 
was 0.88 L and 0.1 L/h, respectively, for a typical neonate weighing 1.48 kg. Simulation of the current dose regimen showed 
that 27.5% of the neonates would achieve the target AUC 0–24h of ≥ 400 mg × h/L, and 70.7% of the neonates would achieve 
it with 12 mg/kg every 8 h.
Conclusion The majority of the neonates were under dosed. Vancomycin 12 mg/kg should be administered every 8 h over 
1 h infusion to improve the likelihood of achieving the AUC 0–24h target of ≥ 400 mg × h/L. This target is considered optimal 
for MRSA infections, where the vancomycin minimum inhibitory concentration is ≤ 1 µg/mL.
Key Points 
In preterm neonates, a vancomycin dose of 15 mg/kg 
every 12 h is inadequate and leads to low plasma expo-
sure in the majority of neonates.
A vancomycin dose of 12 mg/kg every 8 h, administered 
as an infusion over 1 h, is optimum in preterm neonates 
and favours good clinical outcomes.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 8-020-00302 -7) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Preterm neonates have impaired or weaker innate immune 
functions compared with term neonates, which predis-
poses them to the development of bacterial sepsis during 
the neonatal period [1]. Sepsis, mainly due to Klebsiella 
pneumoniae, Staphylococcus aureus, Escherichia coli, 
Acinetobacter spp. and Pseudomonas spp. infection, is the 
major cause of morbidity and mortality among neonates in 
developing countries [2, 3]. In resource-constrained coun-
tries, most of these pathogens are resistant to empiric treat-
ment regimens, including ampicillin and gentamicin [2]. The 
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associated adverse outcome of neonatal sepsis, especially 
in extremely low-birth-weight infants is brain injury, which 
affects neurodevelopment and growth in early childhood [4].
Vancomycin is recommended for the treatment of methi-
cillin-resistant S. aureus (MRSA) in both children and 
adults [5]. The pharmacokinetics of vancomycin vary more 
considerably in preterm neonates than in older children or 
adults. The recommended trough vancomycin concentration 
(Ctrough) of 15–20 mg/L (or µg/mL) for MRSA infections 
in children can exceed the target area under the concentra-
tion–time curve up to 24 h (AUC 0–24h) of 400 mg × h/L in 
preterm neonates for bacteria with a minimum effective con-
centration (MIC) of ≤ 1 µg/mL [5, 6]. The AUC 0–24h-based 
dosing of vancomycin is more favourable than Ctrough-based 
dosing, as the former is safer in terms of development of 
nephrotoxicity [7]. Moreover, one study found that an AUC-
based dosing strategy for vancomycin frequently improved 
therapeutic target attainment compared with a Ctrough-based 
dosing strategy [8].
The pharmacokinetics and dose optimisation of vancomy-
cin have been evaluated in neonates [9–12], but dose recom-
mendations differ considerably among established reference 
sources [13]. An ideal optimised dose regimen should both 
mean the majority of the population attains the pharmaco-
dynamic target and that the probability of reaching a toxic 
pharmacokinetic target is reduced. Therefore, the current 
study assessed the pharmacokinetics of vancomycin (Aspen-
Vancomycin® and Sandoz-Vancocin  CP®) and determined 
the optimal dose regimen in preterm neonates. The second-
ary objective was to assess whether plasma exposure to these 
two brands of vancomycin was similar.
2  Methods
2.1  Patient Information and Study Type
This was a randomised double-blind study involving pre-
term neonates with suspected nosocomial infection who 
were admitted to the neonatal intensive care units (NICUs) 
of Netcare Blaauwberg and N1 City hospitals in South 
Africa. The neonates were randomly allocated to receive 
either Aspen-Vancomycin® or Sandoz-Vancocin  CP®. Each 
neonate received vancomycin 15 mg/kg every 12 h (twice 
daily; BID) via peripheral intravenous line over 60 minutes. 
The physician was blinded to the vancomycin brand and 
treatment group. The gestational age was determined using 
early antenatal ultrasound; if this was not available, the 
new Ballard score was used [14]. Infants were included in 
the study if they had a corrected postmenstrual age (PMA) 
of 29–35 weeks and were excluded if they had renal dys-
function or chromosomal abnormalities. We defined renal 
dysfunction as a lack of or lower than expected serum cre-
atinine decrease in the first week of postnatal life accom-
panied by risk factors such as low Apgar score, respiratory 
distress syndrome and ibuprofen-treated patent ductus arte-
riosus [15]. Neonates needed to have stable renal function 
for the duration of their vancomycin sampling. Demographic 
information such as age, sex, birth weight, current weight 
(at the time of study), gestational age and height were taken 
from the patient medical records. The information on serum 
creatinine and serum albumin levels for blood collected on 
the study day were made available by the hospital labora-
tory. The estimated glomerular filtration rate was calculated 
using Eq. (1) [16].
where eGFR is estimated glomerular filtration rate. The 
C-reactive protein (CRP) test was ordered whenever MRSA 
was suspected. Meropenem and vancomycin were prescribed 
when a premature infant showed signs of sepsis.
2.2  Ethics
The University of the Western Cape ethics committee (cer-
tificate number: 12/2/21) approved the study. Permission 
to conduct the study at two Netcare hospitals was obtained 
from the research department of Netcare hospitals (refer-
ence: UNIV-2012-0008). Written informed consent was 
obtained from the parents of each premature infant enrolled 
in the study. Strict confidentiality was observed, and the 
study was performed in accordance with the Declaration of 
Helsinki [17].
2.3  Vancomycin Dosing, Blood Sampling 
and Plasma Assay
Each premature infant received intravenous vancomycin 
15 mg/kg infused for 60 minutes BID as per NICU pro-
tocol for treatment of suspected MRSA. The blood sam-
ple of 0.3–0.5 mL for Ctrough was drawn just before the 
administration of the third, sixth and ninth doses. Hence, 
each patient had a maximum of three or at least two blood 
samples. Blood was collected in BD Mirotrainer SST™ 
tubes, allowed to clot and then centrifuged to separate 
blood clots from the serum. Vancomycin plasma concen-
tration was analysed on the Architect™ c1600 system using 
particle-enhanced turbidimetric inhibition immunoassay 
(PETINIA). The assay was linear in the range 1.1–100.0 
µg/mL. The lowest limit of quantification was 1.1 µg/mL. 
The accuracy of the assay ranged between 99.3 and 105%. 
The within-run and between-run precision ranged from 1.1 
to 6.1% and from 0.51 to 1.27% of the coefficient of varia-
tion, respectively.
(1)eGFR = 0.33 × height∕(serum creatinine)
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2.4  Pharmacokinetic Analysis
The pharmacokinetic analysis was performed using non-lin-
ear mixed effects modelling implemented in Monolix 2018R2 
software. Since our data set had trough concentrations only, 
we used a Bayesian approach to estimate pharmacokinetic 
parameters and their variabilities. We obtained prior informa-
tion on vancomycin pharmacokinetic parameters in neonates 
for Bayesian estimation (maximum a posteriori estimation) of 
population pharmacokinetic parameters from the literature. 
This prior information was derived from 54 neonates who 
provided peak and trough vancomycin concentrations [18]. 
The estimation algorithm used was stochastic approximation 
expectation maximisation. The Fisher information matrix 
was computed using stochastic approximation, and the like-
lihood was calculated by importance sampling.
We used a one-compartment model as a base pharma-
cokinetic model with the parameters clearance and volume 
of distribution (Vd). The random variation in the population 
pharmacokinetic parameters was described by between-sub-
ject variability (BSV) with an assumption that parameters 
were log-normally distributed. We explored the additive, 
proportional, combined (additive and proportional) and 
exponential error models to model the residual unexplained 
variability. The choice of the error model was based on the 
magnitude of reduction in the objective function (OFV) 
defined as −2 × loglikelihood and goodness-of-fit plots. 
The percentage of the relative standard error (RSE) was the 
measure of precision and was considered when selecting the 
best error model.
Once we had selected the base model, we investigated 
possible covariate effects on pharmacokinetic parameters. We 
performed allometric scaling on disposition parameters using 
either current weight or body surface area (BSA), where the 
exponents 0.75 and 1 were fixed on clearance and Vd, respec-
tively [19]. This was done to adjust for the effect of body 
size. The effect of covariates such as age, PMA, gestational 
age and sex were tested one at a time. Neonates for whom 
albumin, serum creatinine and eGFR values were missing 
were excluded to examine the effect of albumin and eGFR 
on pharmacokinetic parameters. If no significant effect was 
observed, the neonates with missing values were included, 
and then albumin, serum creatinine and eGFR were disre-
garded in the covariate analysis. A covariate normalised by 
its median value was retained if it was statistically significant 
(p ≤ 0.05) using the Wald test, led to a reduction in the BSV 
and OFV of at least 3.84 points.
2.5  Model Evaluation
We assessed how well the data fit in the final pharma-
cokinetic model using goodness-of-fit plots such as 
model-predicted individual concentration versus observed 
concentration, individual weighted residuals (IWRES) ver-
sus time and visual predictive checks (VPC). Additionally, 
we reported the shrinkage in the population pharmacoki-
netic parameters. We evaluated the stability and robustness 
of the model by performing a non-parametric bootstrap 
resampling procedure in Monolix with the aid of Rsmlx 
(R Speaks ‘Monolix’) R package (http://rsmlx .webpo pix.
org). The median values from the 500 bootstrap runs were 
compared with the median (typical) values of the estimated 
pharmacokinetic parameters.
2.6  Assessment of the Current Dose Regimen 
and Optimisation by Monte Carlo Simulation
A pharmacodynamic index ratio (AUC 0–24h/MIC) of ≥ 400 
is recommended as a target to achieve clinical effectiveness 
with vancomycin in MRSA with an MIC of 1 µg/mL [20], 
so we aimed for an AUC 0–24h target of ≥ 400 mg × h/L. We 
assessed the current dose regimen of vancomycin 15 mg/kg 
BID by performing a Monte Carlo simulation of AUC 0–24h 
and Ctrough of 1000 neonates at steady state using Simulx 
(Antony, France: Lixoft SAS, 2018). We recorded the per-
centage of neonates who achieved AUC 0–24h ≥ 400 mg × h/L.
Monte Carlo simulations of 1000 neonates were repeated 
using different plausible vancomycin doses and dosing inter-
vals. This ensured the identification of the optimal dose regi-
men that would result in most of the neonates reaching the 
target AUC 0–24h of ≥ 400 mg × h/L. Identifying the Ctrough 
associated with AUC 0–24h ≥ 400 mg × h/L was important. 
Therefore, we determined the interquartile range of Ctroughs 
from the optimised dose regimen that corresponded to AUC 
0–24h ≥ 400 mg × h/L. We then compared the current dose 
regimen with the optimised regimen in terms of the percent-
age of neonates who achieved the desired target AUC 0–24h.
2.7  Assessment of Plasma Exposure of Vancomycin 
in the Two Treatment Groups
The plasma trough concentrations for neonates assigned to 
Aspen-Vancomycin® or Sandoz-Vancocin  CP® were com-
pared using the Mann–Whitney U test. The comparison was 
carried out across three sampling time points (just before the 
third, sixth and ninth doses) and at all sampling time points.
3  Results
In total, 19 preterm neonates were enrolled in the study. 
They provided a total of 45 plasma concentration–time 
points for vancomycin. Seven neonates had respiratory dis-
tress syndrome; two had jaundice and one had necrotising 
enterocolitis. Table 1 summarizes the demographic infor-
mation, and Fig. 1 shows the observed Ctrough–time profile.
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3.1  Pharmacokinetic Model
The selected base model was a one-compartment pharma-
cokinetic model with parameters  Vd and clearance. The 
exponential error model best described the residual unex-
plained variability on pharmacokinetic parameters. Cur-
rent weight was a better descriptor of body size than was 
BSA. Allometric scaling by fixing the exponents of Vd and 
clearance to 1 and 0.75, respectively, using current weight 
improved the model (∆OFV, − 6.08). This explained 10.7% 
and 7.1% of the variation in Vd and clearance, respectively. 
Estimation of the allometric exponents did not yield better 
results than fixing because parameters were not estimated 
with good precision. The covariates albumin, creatinine 
clearance, serum creatinine, PMA, age, sex and gesta-
tional age had no significant effect on Vd or clearance. The 
parameters of the final pharmacokinetic model are shown 
in Table 2. The RSE for the BSV in clearance was > 50% 
(63.4%), and this implied that the value of BSV in clearance 
was not estimated with good precision. However, the rest of 
the pharmacokinetic parameters were estimated with good 
precision. The individual models for clearance and Vd of an 
ith subject are represented by Eqs. (2) and (3), respectively.
3.2  Model Evaluation
The goodness-of-fit plots (Fig. 2) showed no trend in the 



















Table 1  Demographic characteristics of preterm neonates
BSA body surface area, PMA post-menstrual age
a Data from 17 neonates
b Data from 16 neonates
Characteristic Median (range)
Male/female, n 8/11
Age, days 14 (3–58)
Gestational age, weeks 31 (23–34)
Birth weight, kg 1.27 (0.63–2.69)
Current weight, kg 1.48 (0.925–2.62)
BSA,  m2 0.131 (0.091–0.18)
PMA, weeks 33 (30–34.7)
Albumin, g/L 27 (19–37)a
Serum creatinine, µmol/L 51 (26–74)b
Estimated glomerular filtration rate, mL/
min/1.73 m2
0.28 (0.12–0.51)b
Fig. 1  Observed vancomycin concentrations over time
Table 2  Population 
pharmacokinetic parameters of 
vancomycin in preterm neonates 
and bootstrap values
BSV between-subject variability, CI confidence interval, CL clearance, RSE relative standard error, SD 
standard deviation, Vd volume of distribution, %CV coefficient of variation
a Adjusted by allometric scaling and represented a typical individual with a weight of 1.48 kg




− 1) × 100
Parameter Estimate RSE (%) Shrinkage (%) Bootstrap, median (95% CI)
Vd (L)a 0.884 24 15.7 0.86 (0.804–0.93)
CL (L/h)a 0.102 8.19 4 0.1 (0.09–0.11)
BSV, %CVb
Vd 54 21.4 41 (34–94.6)
CL 4 63.4 9 (2.4–20)
Residual error
Exponential 0.284 13.2 0.277 (0.19–0.36)
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versus predicted concentration. Furthermore, individual 
predicted concentrations were similar to the observed con-
centrations as the regression spline was in agreement with 
the line of unity. This indicated that the data fit well to the 
model. The VPC in Fig. 3 shows that the model generated 
Ctrough well, although a higher variation in the 95th percen-
tile was observed. The results of the 500 bootstrap repli-
cates are presented in Table 2. The population pharmacoki-
netic parameter estimates of the final model were similar to 
the bootstrap median parameters, which indicated that the 
final population pharmacokinetic model was stable and the 
parameters were robust.
3.3  Assessment of the Current Dose Regimen 
and Optimisation
Monte Carlo simulation of 1000 neonates receiving the 
current vancomycin dose of 15  mg/kg BID indicated 
that 27.5% of them would achieve the target AUC 0–24h of 
≥ 400 mg × h/L. Hence, the current dose regimen was not 
optimal, as < 50% of the neonates achieved the recom-
mended target. The optimal dose regimen, found after trying 
several doses and dosing intervals, was 12 mg/kg every 8 h 
(three times daily; TID). This dose regimen led to 70.7% of 
the neonates achieving the recommended target AUC 0–24h of 
≥ 400 mg × h/L. Figure 4 compares the distributions of the 
Fig. 2  Goodness-of-fit plots: population and individual predicted concentration versus time. Time and predicted concentration versus individual 
weighted residuals
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current and optimised vancomycin dose regimens and shows 
their corresponding Ctrough.
The median (interquartile range [IQR]) Ctrough for neo-
nates who achieved AUC 0–24h ≥ 400  mg × h/L was 11 
(8–14) µg/mL. The median (IQR) AUC 0–24h and Ctrough 
for the current dose regimen was 366 (326–406) mg × h/L 
and 5.88 (3.3–8.4) µg/mL, respectively. Meanwhile, for the 
optimised dose regimen, the AUC 0–24h and Ctrough were 440 
(391–491) mg × h/L and 9.4 (6.6–12.6) µg/mL, respectively. 
The percentage of neonates with Ctrough > 20 µg/mL was 0.5.
3.4  Comparison of Vancomycin Plasma Exposure 
in Two Treatment Groups
At all sampling time points (just before administration of the 
third, sixth and ninth doses), vancomycin plasma concentra-
tion was significantly higher with Aspen-Vancomycin® than 
with Sandoz-Vancocin  CP® (p = 0.015) (Table 3). However, 
vancomycin concentrations measured at specific time points 
(23.8, 59.8 and 95.8 h) were similar for Aspen-Vancomycin® 
and Sandoz-Vancocin  CP® (p > 0.05).
4  Discussion
In this study of preterm neonates, a one-compartment phar-
macokinetic model with linear elimination best described 
the pharmacokinetics of vancomycin. It was necessary to use 
a Bayesian approach to estimate the pharmacokinetic param-
eters as our data set included only Ctrough concentrations. 
A Bayesian approach allow the estimation of pharmacoki-
netic parameters based on the data but also consider prior 
information from the literature. Hence, the pharmacokinetic 
parameters estimated in the current study were comparable 
with those reported in a similar population of neonates with 
ranges of 0.58–1.19 L and 0.054–0.07 L/h for Vd and clear-
ance, respectively [9, 21–23]. We observed a high variation 
in the Vd (54%), which could not be explained by covari-
ates tested. Other studies involving paediatric populations 
reported similarly high variations in Vd (43 and 77%) [24, 
25]. In contrast, some studies in neonatal populations 
reported low variations in vancomycin Vd (32 and 29.4%) 
[9, 18]. Studies [26–28] have shown sepsis to be associ-
ated with high values of Vd due to the increase in capillary 
permeability that results in interstitial oedema. This may 
warrant administration of higher doses in septic patients to 
achieve the target concentration. The high variation in the Vd 
of the current study could have been due to differences in the 
degree of sepsis that the neonates had during the treatment 
period. Inflammatory markers such as CRP and erythrocyte 
sedimentation rate [29] could have explained this variation 
in Vd, but we did not have these markers in our data. In some 
studies [9, 21, 30], PMA and serum creatinine were statisti-
cally significant covariates that explained the BSV in van-
comycin clearance. The non-statistically significant effect of 
PMA and serum creatinine on clearance in the current study 
could be due to the small sample size and narrow variations 
in PMA and serum creatinine values. Nevertheless, our find-
ings are consistent with those of Germovsek et al. [18], who 
reported that serum creatinine had no significant effect on 
vancomycin clearance.
The assessment of the current vancomycin dose regimen 
of 15 mg/kg BID, using Monte Carlo simulation, indicated 
that only 27.5% of the neonates would achieve the recom-
mended target AUC 0–24h of ≥ 400 mg × h/L for an MIC of 
1 µg/mL. Similarly, other studies [21, 23, 24] reported that a 
small percentage (12.7–41%) of neonates attaining the van-
comycin target concentration/AUC 0–24h with vancomycin 
10–15 mg/kg every 6 h, TID or BID. The clinical conse-
quences of low vancomycin exposure are prolonged dura-
tion of bacteraemia [31] and development of drug-resistant 
bacterial strains [32].
An optimal dose regimen should increase the probabil-
ity of most patients achieving the target pharmacodynamic 
index with no or few patients in the pharmacokinetic toxic 
range. We determined a vancomycin dose of 12 mg/kg TID 
to be optimal in this population of neonates with sepsis due 
to suspected MRSA infection. This optimised dose regimen 
increased the percentage of neonates attaining target AUC 
0–24h from 27.7 to 70.7%. The Ctroughs associated with the 
AUC 0–24h of ≥ 400 mg × h/L ranged between 8 and 14 µg/
mL. This is consistent with values reported in previous stud-
ies, where vancomycin AUC 0–24h ≥ 400 mg × h/L was associ-
ated with a Ctrough range of 7–10 µg/mL [33, 34].
Overall, plasma exposure to vancomycin differed between 
the treatment groups receiving different brands of vanco-
mycin. This clarifies that variations in vancomycin plasma 
Fig. 3  Visual predictive check for vancomycin for 1000 simulations 
of the final pharmacokinetic model. The upper, middle and lower 
solid lines represent the 95th, 50th and 5th percentiles, respectively; 
the dots represent observed trough concentrations
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Fig. 4  The exposure (AUC 0-24h 
and  Cmax) profiles for the cur-
rent and optimised vancomycin 
dose regimen. A dotted line on 
the AUC 0-24h axis represents the 
target AUC 0-24h; the two dotted 
lines on the  Cmax axis represent 
the upper and lower quartiles 
values of  Cmax associated with 
AUC 0-24h ≥400 mg × h/L.  
AUC 0-24h area under the concen-
tration–time curve up to 24 h, 
Cmax peak plasma concentration
Table 3  Plasma  concentrationsa 
of vancomycin in the treatment 
groups
a Concentrations are presented as µg/mL, median (range)
*Statistically significant
Sampling times (h) Aspen-Vancomycin® Sandoz-Vancocin  CP® p value
23.8 11.5 (8–19) 10 (1–14) 0.1
59.8 9 (6–16) 9 (5–14) 0.52
95.8 13.5 (10–16) 7.5 (4–16) 0.09
All time points 11 (6–19) 9 (1–16) 0.015*
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exposure in preterm neonates may be attributable to the use 
of different brands of vancomycin commonly used at the 
hospital.
Our study has some limitations. The sample was small 
and from a homogenous population. Hence, the likelihood of 
finding significant covariates on the pharmacokinetic param-
eters was low. We could only measure trough concentrations 
of vancomycin, and no blood was drawn during the distribu-
tion phase, which could result in estimations of Vd with low 
precision. We also reported low variations in clearance (4 
vs. 32%), which was lower than that reported in the litera-
ture [18] and could have underestimated the variations in 
simulated AUC. However, we circumvented this problem by 
using a Bayesian approach (a priori information) to estimate 
the pharmacokinetic parameters. Additionally, prior infor-
mation on vancomycin pharmacokinetics used in Bayesian 
estimations of pharmacokinetic parameters in our study was 
derived from the data that had both peak and trough con-
centrations. The number of neonates was also greater than 
in our study [18].
5  Conclusions
The current vancomycin dose regimen in preterm neona-
tal populations is inappropriate, as most neonates are likely 
to be under dosed. Based on Monte Carlo simulation, we 
propose a vancomycin optimal dose regimen of 12 mg/kg 
TID as an infusion lasting for 60 min in neonates meeting 
the inclusion criteria of the current study. Additionally, the 
proposed regimen is unlikely to result in Ctroughs of > 20 µg/
mL, thereby minimising the likelihood of overexposure and 
the risk of nephrotoxicity.
Acknowledgements The authors thank Netcare Ltd for providing 
access to conduct the study at the two Netcare hospitals. We thank the 
parents who gave consent to include their infants in the study.
Author Contributions Mwila Mulubwa analysed/interpreted the data 
and drafted the manuscript. Heletje Aletta Griesel conceived the idea, 
wrote the study protocol and implemented the study. Pierre Mugabo 
designed and supervised the study. Ricky Dippenaar recruited patients 
and conducted blood sample collection for vancomycin and biological 
tests. Lizelle van Wyk coordinated blood sample collection for van-
comycin plasma levels and biological tests. All authors reviewed and 
approved the final draft.
Compliance with Ethical Standards 
Funding No specific funding was received for the conduct of this study 
or preperation of this manuscript.
Conflicts of interest Mwila Mulubwa, Heletje Aletta Griesel, Pierre 
Mugabo, Ricky Dippenaar, and Lizelle van Wyk have no conflicts of 
interest that are directly relevant to the content of this article.
Ethical approval The ethics committee of the University of the Western 
Cape approved the study (certificate number: 12/2/21). Permission was 
sought from the research department of Netcare hospital (reference: 
UNIV-2012-0008) to conduct the study.
Informed consent Written informed consent was obtained from the 
parents of each premature infant before enrolment in the study. Strict 
confidentiality was observed, and the study was carried out in accord-
ance with the principles outlined in the Declaration of Helsinki. The 
parents had the right to withdraw their infants from the study at any 
time without giving a reason.
Open Access This article is licensed under a Creative Commons Attri-
bution-NonCommercial 4.0 International License, which permits any 
non-commercial use, sharing, adaptation, distribution and reproduction 
in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative 
Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons 
licence and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission 
directly from the copyright holder.To view a copy of this licence, visit 
http://creat iveco mmons .org/licen ses/by-nc/4.0/.
References
 1. Tissieres P, Ochoda A, Dunn-Siegrist I, Drifte G, Morales M, 
Pfister R, et al. Innate immune deficiency of extremely prema-
ture neonates can be reversed by interferon-gamma. PLoS One. 
2012;7:e32863.
 2. Zaidi AKM, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Gold-
mann DA. Hospital-acquired neonatal infections in developing 
countries. Lancet. 2005;365:1175–88.
 3. Kayange N, Kamugisha E, Mwizamholya DL, Jeremiah S, Mshana 
SE. Predictors of positive blood culture and deaths among neo-
nates with suspected neonatal sepsis in a tertiary hospital, 
Mwanza-Tanzania. BMC Pediatr. 2010;10:39.
 4. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz 
SR, Vohr B, et al. Neurodevelopmental and growth impairment 
among extremely low-birth-weight infants with neonatal infection. 
JAMA. 2004;292:2357–65.
 5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, 
et al. Clinical practice guidelines by the Infectious Diseases Soci-
ety of America for the treatment of methicillin-resistant Staphy-
lococcus aureus infections in adults and children. Clin Infect Dis. 
2011;52:e18–55.
 6. Alsultan A, Abouelkheir M, Alqahtani S, Aljabri A, Somily AM, 
Alsubaie S, et al. Vancomycin monitoring in pediatric patients. 
Pediatr Infect Dis J. 2018;37:880–5.
 7. Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost 
R, et al. A quasi-experiment to study the impact of vancomycin 
area under the concentration-time curve-guided dosing on vanco-
mycin-associated nephrotoxicity. Antimicrob Agents Chemother. 
2017;61:e01293–17.
 8. Meng L, Wong T, Huang S, Mui E, Nguyen V, Espinosa G, et al. 
Conversion from vancomycin trough concentration-guided dosing 
to area under the curve-guided dosing using two sample measure-
ments in adults: implementation at an Academic Medical Center. 
Pharmacotherapy. 2019;39:433–42.
 9. Kato H, Hagihara M, Nishiyama N, Koizumi Y, Mikamo H, Mat-
suura K, et al. Assessment of optimal initial dosing regimen with 
113Assessment of Vancomycin Pharmacokinetics
vancomycin pharmacokinetics model in very low birth weight 
neonates. J Infect Chemother. 2017;23:154–60.
 10. Marques-Minana MR, Saadeddin A, Peris JE. Population pharma-
cokinetic analysis of vancomycin in neonates. A new proposal of 
initial dosage guideline. Br J Clin Pharmacol. 2010;70:713–20.
 11. Cies JJ, Moore WS, Nichols K, Knoderer CA, Carella DM, Chopra 
A. Population pharmacokinetics and pharmacodynamic target 
attainment of vancomycin in neonates on extracorporeal life sup-
port. Pediatr Crit Care Med. 2017;18:977–85.
 12. James A, Koren G, Milliken J, Soldin S, Prober C. Vancomycin 
pharmacokinetics and dose recommendations for preterm infants. 
Antimicrob Agents Chemother. 1987;31:52–4.
 13. Liem TBY, Slob EMA, Termote JUM, Wolfs TFW, Egberts ACG, 
Rademaker CMA. Comparison of antibiotic dosing recommenda-
tions for neonatal sepsis from established reference sources. Int J 
Clin Pharm. 2018;40:436–43.
 14. Ballard J, Khoury J, Wedig K, Wang L, Eilers-Walsman B, Lipp 
R. New Ballard Score, expanded to include extremely premature 
infants. J Pediatr. 1991;119:417–23.
 15. Walker MW, Clark RH, Spitzer AR. Elevation in plasma cre-
atinine and renal failure in premature neonates without major 
anomalies: terminology, occurrence and factors associated with 
increased risk. J Perinatol. 2011;31:199–205.
 16. Brion LP, Fleischman AR, McCarton C, Schwartz GJ. A simple 
estimate of glomerular filtration rate in low birth weight infants 
during the first year of life: noninvasive assessment of body com-
position and growth. J Pediatr. 1986;109:698–707.
 17. General Assembly of the World Medical Association. World 
Medical Association Declaration of Helsinki: ethical principles 
for medical research involving human subjects. J Am Coll Dent. 
2014;81:14–8.
 18. Germovsek E, Osborne L, Gunaratnam F, Lounis SA, Busquets 
FB, Standing JF, et al. Development and external evaluation of 
a population pharmacokinetic model for continuous and inter-
mittent administration of vancomycin in neonates and infants 
using prospectively collected data. J Antimicrob Chemother. 
2019;74:1003–11.
 19. Anderson BJ, Holford NHG. Mechanistic basis of using body size 
and maturation to predict clearance in humans. Drug Metab Phar-
macokinet. 2009;24:25–36.
 20. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, 
Billeter M, et al. Therapeutic monitoring of vancomycin in adult 
patients: a consensus review of the American Society of Health-
System Pharmacists, the Infectious Diseases Society of America, 
and the Society of Infectious Diseases Pharmacists. Am J Health 
Syst Pharm. 2009;66:82–98.
 21. Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X, et al. Population 
pharmacokinetics of vancomycin and AUC-guided dosing in 
Chinese neonates and young infants. Eur J Clin Pharmacol. 
2018;74:921–30.
 22. Mehrotra N, Tang L, Phelps SJ, Meibohm B. Evaluation of vanco-
mycin dosing regimens in preterm and term neonates using Monte 
Carlo simulations. Pharmacotherapy. 2012;32:408–19.
 23. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-
Aigrain E. Vancomycin continuous infusion in neonates: dosing 
optimisation and therapeutic drug monitoring. Arch Dis Child. 
2013;98:449–53.
 24. Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme 
T, et al. Population pharmacokinetics and dosing optimization of 
vancomycin in children with malignant hematological disease. 
Antimicrob Agents Chemother. 2014;58:3191–9.
 25. Lamarre P, Lebel D, Ducharme MP. A population pharmacoki-
netic model for vancomycin in pediatric patients and its predic-
tive value in a naive population. Antimicrob Agents Chemother. 
2000;44:278–82.
 26. Marik P. Aminoglycoside volume of distribution and illness 
severity in critically ill septic patients. Anaesth Intensive Care. 
1993;21:172–3.
 27. Kieft H, Hoepelman A, Knupp C, Van Dijk A, Branger J, 
Struyvenberg A, et  al. Pharmacokinetics of cefepime in 
patients with the sepsis syndrome. J Antimicrob Chemother. 
1993;32(suppl_B):117–22.
 28. Tang G, Tang J, Lin B, Kong C, Lee T. Factors affecting gen-
tamicin pharmacokinetics in septic patients. Acta Anaesthesiol 
Scand. 1999;43:726–30.
 29. Harrison M. Erythrocyte sedimentation rate and C-reactive pro-
tein. Aust Prescr. 2015;38:93–4.
 30. Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski 
EK, Spigarelli MG, et al. Predictive performance of a vancomycin 
population pharmacokinetic model in neonates. Infect Dis Ther. 
2015;4:187–98.
 31. Hsu AJ, Hamdy RF, Huang Y, Olson JA, Ghobrial S, Gerber JS, 
et al. Association between vancomycin trough concentrations and 
duration of methicillin-resistant Staphylococcus aureus bactere-
mia in children. J Pediatr Infect Dis Soc. 2018;7:338–41.
 32. Drlica K. The mutant selection window and antimicrobial resist-
ance. J Antimicrob Chemother. 2003;52:11–7.
 33. Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen 
N, et al. Improved vancomycin dosing in children using area under 
the curve exposure. Pediatr Infect Dis J. 2013;32:e155–63.
 34. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin 
trough serum concentration for treating invasive methicil-
lin-resistant Staphylococcal infections. Pediatr Infect Dis J. 
2013;32:1077–9.
